SIGA Technologies To Announce First Quarter 2007 Results of Operations Read more about SIGA Technologies To Announce First Quarter 2007 Results of Operations SIGA Passes First Hurdle With Lassa Fever Antivirial ST-193 Read more about SIGA Passes First Hurdle With Lassa Fever Antivirial ST-193 SIGA Technologies To Join The Russell Microcap Index Read more about SIGA Technologies To Join The Russell Microcap Index ST-246 Completely Prevents Mortality in Symptomatic Orthopox Virus Infected Primates Read more about ST-246 Completely Prevents Mortality in Symptomatic Orthopox Virus Infected Primates SIGA Technologies to Announce Third Quarter 2007 Results Of Operations Read more about SIGA Technologies to Announce Third Quarter 2007 Results Of Operations SIGA Cheif Scientific Officer, Dennis Hruby To Present ST-246 Progress And Human Clinical Safety Study Data To The World Health Organization (WHO) Read more about SIGA Cheif Scientific Officer, Dennis Hruby To Present ST-246 Progress And Human Clinical Safety Study Data To The World Health Organization (WHO) SIGA Completes 21 Day Multi-dose Human Clinical Safety And Dose-ranging Trial Of Its Lead Smallpox Drug ST-246 Read more about SIGA Completes 21 Day Multi-dose Human Clinical Safety And Dose-ranging Trial Of Its Lead Smallpox Drug ST-246 SIGA CEO, Dr. Eric Rose, Selected To Serve As Member of National Biodefense Science Board Read more about SIGA CEO, Dr. Eric Rose, Selected To Serve As Member of National Biodefense Science Board SIGA to Present at The 26th Annual JPMorgan Healthcare Conference Read more about SIGA to Present at The 26th Annual JPMorgan Healthcare Conference Gregory Wade Ph.D. Gregory Wade Ph.D. Wedbush Pac Grow Lifesciences greg.wade@wedbush.com Pagination First page « First Previous page ‹ Previous … Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Current page 27 Page 28 Next page Next › Last page Last » Subscribe to
SIGA Technologies To Announce First Quarter 2007 Results of Operations Read more about SIGA Technologies To Announce First Quarter 2007 Results of Operations
SIGA Passes First Hurdle With Lassa Fever Antivirial ST-193 Read more about SIGA Passes First Hurdle With Lassa Fever Antivirial ST-193
SIGA Technologies To Join The Russell Microcap Index Read more about SIGA Technologies To Join The Russell Microcap Index
ST-246 Completely Prevents Mortality in Symptomatic Orthopox Virus Infected Primates Read more about ST-246 Completely Prevents Mortality in Symptomatic Orthopox Virus Infected Primates
SIGA Technologies to Announce Third Quarter 2007 Results Of Operations Read more about SIGA Technologies to Announce Third Quarter 2007 Results Of Operations
SIGA Cheif Scientific Officer, Dennis Hruby To Present ST-246 Progress And Human Clinical Safety Study Data To The World Health Organization (WHO) Read more about SIGA Cheif Scientific Officer, Dennis Hruby To Present ST-246 Progress And Human Clinical Safety Study Data To The World Health Organization (WHO)
SIGA Completes 21 Day Multi-dose Human Clinical Safety And Dose-ranging Trial Of Its Lead Smallpox Drug ST-246 Read more about SIGA Completes 21 Day Multi-dose Human Clinical Safety And Dose-ranging Trial Of Its Lead Smallpox Drug ST-246
SIGA CEO, Dr. Eric Rose, Selected To Serve As Member of National Biodefense Science Board Read more about SIGA CEO, Dr. Eric Rose, Selected To Serve As Member of National Biodefense Science Board
SIGA to Present at The 26th Annual JPMorgan Healthcare Conference Read more about SIGA to Present at The 26th Annual JPMorgan Healthcare Conference